Prothena Corporation

Prothena Corporation company information, Employees & Contact Information

Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together.

Company Details

Employees
155
Founded
-
Address
77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands,united States
Phone
650 837 8550
Email
in****@****ena.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Dublin, 2
Looking for a particular Prothena Corporation employee's phone or email?

Prothena Corporation Questions

News

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease - Yahoo Finance

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease Yahoo Finance

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Business Wire

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference Business Wire

Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential - Stock Titan

Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential Stock Titan

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint - Business Wire

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint Business Wire

Prothena to Report First Quarter 2025 Financial Results on May 8 - FinancialContent

Prothena to Report First Quarter 2025 Financial Results on May 8 FinancialContent

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - Yahoo Finance

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights Yahoo Finance

Prothena Announces Corporate Restructuring - Business Wire

Prothena Announces Corporate Restructuring Business Wire

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer's Disease Clinical Trial - Walgreens Boots Alliance

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer's Disease Clinical Trial Walgreens Boots Alliance

Prothena lays off 63% of employees in fallout from phase 3 amyloidosis drug fail - Fierce Biotech

Prothena lays off 63% of employees in fallout from phase 3 amyloidosis drug fail Fierce Biotech

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program - Business Wire

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program Business Wire

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 - FinancialContent

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 FinancialContent

Prothena reburies drug after 2nd swing at rare disease misses, plans 'substantial' layoffs - Fierce Biotech

Prothena reburies drug after 2nd swing at rare disease misses, plans 'substantial' layoffs Fierce Biotech

Prothena Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire

Prothena Reports First Quarter 2025 Financial Results and Business Highlights Business Wire

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - Business Wire

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease Business Wire

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease - Business Wire

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease Business Wire

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights - Business Wire

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights Business Wire

Prothena Announces Leadership Team Updates - Business Wire

Prothena Announces Leadership Team Updates Business Wire

Q&A: Understanding protein dysregulation key to preventing neurodegeneration - Healio

Q&A: Understanding protein dysregulation key to preventing neurodegeneration Healio

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors - Business Wire

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors Business Wire

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial - ScienceDirect.com

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial ScienceDirect.com

Prothena promotes one exec while another leaves—Chutes & Ladders - Fierce Biotech

Prothena promotes one exec while another leaves—Chutes & Ladders Fierce Biotech

Prothena Surges After Parkinson's Drug Misses Primary Endpoint - Seeking Alpha

Prothena Surges After Parkinson's Drug Misses Primary Endpoint Seeking Alpha

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme - GlobeNewswire

Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme GlobeNewswire

Roche And Prothena: Why Moving On Makes Sense (OTCMKTS:RHHBY) - Seeking Alpha

Roche And Prothena: Why Moving On Makes Sense (OTCMKTS:RHHBY) Seeking Alpha

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors - GlobeNewswire

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors GlobeNewswire

What do new Alzheimer’s treatments on the horizon mean for patients? - statnews.com

What do new Alzheimer’s treatments on the horizon mean for patients? statnews.com

Billy Dunn’s Prothena Board Position Reignites Ethical Debate - BioSpace

Billy Dunn’s Prothena Board Position Reignites Ethical Debate BioSpace

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 - GlobeNewswire

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 GlobeNewswire

FDA Clears IND for Antiamyloid Antibody for Alzheimer Disease, Set to Initiate Trial - NeurologyLive

FDA Clears IND for Antiamyloid Antibody for Alzheimer Disease, Set to Initiate Trial NeurologyLive

Novo Nordisk puts $1.2B on the table for Prothena's ATTR drug, teeing up Alnylam challenge and cardiovascular expansion - Fierce Biotech

Novo Nordisk puts $1.2B on the table for Prothena's ATTR drug, teeing up Alnylam challenge and cardiovascular expansion Fierce Biotech

Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer - GlobeNewswire

Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer GlobeNewswire

PRTA Stock Price and Chart — NASDAQ:PRTA - TradingView

PRTA Stock Price and Chart — NASDAQ:PRTA TradingView

Top Prothena Corporation Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant